Ascendis Pharma ASMEX:ASNDN 37 PS Ratio is 12.90 as of Jun. 25, 2026, which is 10% below its 10-year median of 14.26. GuruFocus rates MEX:ASNDN with a GF Score™ of 37/100. The stock has 1 warning sign investors should review. Among 937 Biotechnology companies, Ascendis Pharma AS ranks worse than 60.3% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Ascendis Pharma AS's share price is MXN3851.44.
Ascendis Pharma AS's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was MXN298.45. Hence, Ascendis Pharma AS's PS Ratio for today is 12.90.
The historical rank and industry rank for Ascendis Pharma AS's PS Ratio or its related term are showing as below:
MEX:ASNDN'
s PS Ratio Range Over the Past 10 Years
Min: 13.04 Med: 14.26 Max: 15.31
Current: 14.74
During the past 13 years, Ascendis Pharma AS's highest PS Ratio was 15.31. The lowest was 13.04. And the median was 14.26.
MEX:ASNDN's PS Ratio is ranked worse than 60.3% of 937
companies
in the Biotechnology industry
Industry Median: 9.42
vs MEX:ASNDN: 14.74
During the past 12 months, the average Revenue per Share Growth Rate of Ascendis Pharma AS was 143.80% per year.
During the past 3 years, the average Revenue per Share Growth Rate was 143.20% per year.
During the past 5 years, the average Revenue per Share Growth Rate was 171.10% per year.
During the past 10 years, the average Revenue per Share Growth Rate was 54.30% per year.
During the past 13 years, Ascendis Pharma AS's highest 3-Year average Revenue per Share Growth Rate was 245.10% per year. The lowest was -62.40% per year. And the median was 20.50% per year.
Back to Basics: PS Ratio
Ascendis Pharma AS (MEX:ASNDN) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
Ascendis Pharma AS PS Ratio Related Terms
Ascendis Pharma AS PS Ratio Historical Data
* Premium members only.
The historical data trend for Ascendis Pharma AS's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MEX:ASNDN vs SMMT, BBIO, JAZZ: PS Ratio Comparison
For the Biotechnology subindustry, Ascendis Pharma AS's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ascendis Pharma AS PS Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Ascendis Pharma AS's PS Ratio distribution charts can be found below:
* The bar in red indicates where Ascendis Pharma AS's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Ascendis Pharma AS's Share Price of today is MXN3851.44. Ascendis Pharma AS's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN298.45.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Ascendis Pharma AS (MEX:ASNDN) has a PS Ratio of 12.90 as of Jun. 25, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Ascendis Pharma AS and its competitors. This is 10% below median its historical median of 14.26. Over the past decade, Ascendis Pharma AS's PS Ratio has ranged from 13.04 to 15.31. According to the industry distribution chart, Ascendis Pharma AS ranks #565 out of 937 companies in the Biotechnology industry, placing it in the top 60.3%.
Is Ascendis Pharma AS's PS Ratio too high?
Ascendis Pharma AS's current PS Ratio of 12.90 is 10% below median its 10-year median of 14.26. Over the past 10 years, this metric has ranged from a low of 13.04 to a high of 15.31. The Biotechnology industry median PS Ratio is 9.42. Ascendis Pharma AS's value of 12.90 is 36.9% above this industry median. Based on the distribution chart, Ascendis Pharma AS ranks #565 out of 937 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Ascendis Pharma AS has a GF Score™ of 37/100, reflecting its overall financial health beyond just this single metric.
How does Ascendis Pharma AS's PS Ratio compare to SMMT and BBIO?
According to the Biotechnology industry distribution chart, Ascendis Pharma AS ranks #565 out of 937 companies for PS Ratio. This places Ascendis Pharma AS in the lower half of its industry. The industry median PS Ratio is 9.42. Ascendis Pharma AS's value of 12.90 is 36.9% above this benchmark. Historically, Ascendis Pharma AS's own PS Ratio has ranged from 13.04 to 15.31 over the past decade. While the company's 10-year median is 14.26 vs. the industry median of 9.42, Ascendis Pharma AS has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Biotechnology company?
The median PS Ratio among Biotechnology companies is 9.42, based on 937 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Ascendis Pharma AS's current PS Ratio of 12.90 is 36.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Ascendis Pharma AS and its competitors. For the Biotechnology industry, the median PS Ratio is 9.42 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ascendis Pharma AS's current PS Ratio is 12.90, which is 10% below median its own 10-year median of 14.26. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ascendis Pharma AS stock overvalued right now?
Ascendis Pharma AS (MEX:ASNDN) has a current PS Ratio of 12.90. The current PS Ratio is 12.90, which is 10% below median its 10-year median of 14.26 and 36.9% above the Biotechnology industry median of 9.42. Ascendis Pharma AS's overall GF Score™ is 37/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Ascendis Pharma AS (MEX:ASNDN), the current PS Ratio is 12.90 as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Ascendis Pharma AS is a biopharmaceutical company that applies its TransCon technology platform to make a meaningful difference for patients. The firm's product pipeline includes Endocrinology and Oncology, which includes TransCon PTH, TransCon CNP, and others. It operates in the United States, Europe, and the rest of the world and derives the majority of its revenue from the United States.
37GF Score
Get the complete analysis for MEX:ASNDN
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:ASNDN has been successfully added to your 
